GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Vitrolife (STO:VITR):
Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January-March 2012. The presentation will be held in English.
Time: Friday, April 20, 2012 at 10 a.m. CET.
Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=533433&Conf=183317
or shortly before the conference starts on:
Sweden dial in number: +46 (0)8 505 201 10
UK dial in number: +44 (0)20 7162 0077
Conference name: Vitrolife, conference ID: 915308
Vitrolife participants:
Thomas Axelsson, CEO
Mikael Engblom, CFO
The press release for Vitrolife’s interim report will be released at 3 p.m. CET on Thursday, April 19.
Before the conference call, slides will be available at the company web page, www.vitrolife.com/en/Corporate/.
A recorded version of the conference call will be available for seven days on number +46 (0)8 505 203 33 (Sweden) or +44 (0)20 7031 4064 (UK), access code 915308.
Gothenburg, April 12, 2012
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
VITROLIFE AB (publ)
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation (http://www.xvivoperfusion.com/transplantation/) product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.
Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
This information was brought to you by Cision http://www.cisionwire.com